Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of FOR-6219 in Postmenopausal Women
NCT04686669Phase 1Completed
- Sponsor
- Forendo Pharma
- Start
- Dec 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of linustedastat in endometriosis (6 arms), sponsored by Forendo Pharma. Primary endpoints: Ratio of Peak Plasma Concentration (Cmax) after single dose of FOR-6219 tablet (fasted) over soft gelatine capsule (fasted), Ratio of Area under the plasma concentration versus time curve (AUC) after single dose of FOR-6219 tablet (fasted) over soft gelatine capsule (fasted) and 2 more. Started Dec 2020; status: completed.
02
Drugs
linustedastat
03
Conditions
endometriosis
Beyond the preview
Go deeper on NCT04686669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04686669.